株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌免疫療法・腫瘍溶解性ウイルス療法:技術と世界市場

Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

発行 BCC Research 商品コード 298488
出版日 ページ情報 英文 164 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.34円で換算しております。
Back to Top
癌免疫療法・腫瘍溶解性ウイルス療法:技術と世界市場 Cancer Immunology and Oncolytic Virology: Technologies and Global Markets
出版日: 2017年05月04日 ページ情報: 英文 164 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の癌免疫療法市場は、2016年の730億米ドルから、2021年には965億米ドルに達し、2016年〜2021年のCAGR (複合年間成長率) で、5.7%の成長が予測されています。

当レポートでは、世界の癌免疫療法・腫瘍溶解性ウイルス療法市場について調査分析し、概要、市場動向、市場需要に影響を与える要因、最新の動向、市場構造、市場規模、主要薬セグメント、技術動向、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 サマリーとハイライト

第3章 概要

  • 概要
    • 癌免疫学の歴史と現状
    • 癌とは
    • 癌治療
    • 癌治療の課題
    • 癌と免疫システム
    • 免疫療法
    • 併用免疫療法、など

第4章 癌免疫療法の概要

  • 癌免疫療法の概要
    • 免疫システムと免疫療法
    • 治療用モノクローナル抗体
    • チェックポイント阻害剤
    • BRM
    • ワクチン
    • その他、など

第5章 腫瘍溶解性ウイルス学

  • 腫瘍溶解性ウイルス学
    • 腫瘍溶解性ウイルス療法

第6章 主要市場

  • 主要市場
    • 免疫療法製品の市場
    • 腫瘍溶解性ウイルス療法製品の市場

第7章 企業プロファイル

  • 企業プロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM129B

The global cancer immunotherapy market should reach $96.5 billion by 2021 from $73.0 billion in 2016 at a compound annual growth rate (CAGR) of 5.7%, from 2016 to 2021.

Report Includes

  • An overview of the global markets for cancer immunotherapies and oncolytic virology.
  • Analyses of global market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Analyses of factors influencing market demand, such as clinical guidelines, demographic changes, and market saturation.
  • Information covering the latest trends, market structure, market size, key drug segments, and trends in technology.
  • Coverage of colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines, and other cancer treatment immunology products.
  • Technological discussions, including the current state, newly issued patents, and pending applications.
  • Profiles of leading companies in the industry.

Report Scope

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Analyst Credentials

Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. He possesses extensive pharmaceutical research and development experience and has participated in projects for various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama based on the high quality of his work and excellence in the fields of research.

Table of Contents

List of Tables

  • TABLE 1 Summary Table: Global Market for Cancer Immunotherapy, by Region, Through 2021 ($ Millions)
  • TABLE 2 Stages of Lung Cancer
  • TABLE 3 Approved Monoclonal Antibodies
  • TABLE 4 Approved Antibody Drug Conjugates
  • TABLE 5 Selected Therapeutic Monoclonal Antibodies in Clinical Trial
  • TABLE 6 Approved Checkpoint Inhibitors
  • TABLE 7 Selected Checkpoint Inhibitors in Clinical Trials
  • TABLE 8 Selected Approved Interferon Alpha Analogues
  • TABLE 9 Selected Approved Colony-Stimulating Factors
  • TABLE 10 Selected Clinical-Stage Cancer Vaccines in Development
  • TABLE 11 Selected Clinical-Stage Small-Molecule Immunotherapies in Development
  • TABLE 12 Global Market for Immunotherapy Products, by Region, Through 2021 ($ Millions)
  • TABLE 13 Global Market for Immunotherapy Products, by Treatment Category, Through 2021 ($ Millions)
  • TABLE 14 U.S. Market for Immunotherapy Products, by Treatment Category, Through 2021 ($ Millions)
  • TABLE 15 European Market for Immunotherapy Products, by Treatment Category, Through 2021 ($ Millions)
  • TABLE 16 Japanese Market for Immunotherapy Products, by Treatment Category, Through 2021 ($ Millions)
  • TABLE 17 Rest of the World Market for Immunotherapy Products, by Treatment Category, Through 2021 ($ Millions)
  • TABLE 18 Global Market for Immunotherapy Products, by Cancer Indication, Through 2021 ($ Millions)
  • TABLE 19 Global Market for Immunotherapy Products for Lung Cancer Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 20 Global Market for Immunotherapy Products for Breast Cancer Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 21 Global Market for Immunotherapy Products for Leukemia Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 22 Global Market for Immunotherapy for Myeloma Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 23 Global Market for Immunotherapy Products for Colorectal Cancer Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 24 Global Market for Immunotherapy Products for Lymphoma Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 25 Global Market for Immunotherapy Products for Melanoma Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 26 Global Market for Immunotherapy Products for Kidney Cancer Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 27 Global Market for Immunotherapy Products for Bladder Cancer Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 28 Global Market for Immunotherapy Products for Head and Neck Cancer Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 29 Global Market for Immunotherapy Products for Stomach Cancer Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 30 Global Market for Immunotherapy Products for Other Cancer Treatment, by Region, Through 2021 ($ Millions)
  • TABLE 31 Global Market for Therapeutic Antibodies, by Region, Through 2021 ($ Millions)
  • TABLE 32 Global Market for Checkpoint Inhibitors, by Region, Through 2021 ($ Millions)
  • TABLE 33 Global Market for Interleukins, by Region, Through 2021 ($ Millions)
  • TABLE 34 Global Market for Interferons, by Region, Through 2021 ($ Millions)
  • TABLE 35 Global Market for Colony-Stimulating Factors, by Region, Through 2021 ($ Millions)
  • TABLE 36 Global Market for Small Kinase Inhibitors, by Region, Through 2021 ($ Millions)
  • TABLE 37 Global Market for Proteasome Inhibitors, by Region, Through 2021 ($ Millions)
  • TABLE 38 Global Market for Immunomodulators, by Region, Through 2021 ($ Millions)
  • TABLE 39 Global Market for Cancer Vaccines, by Region, Through 2021 ($ Millions)
  • TABLE 40 Global Market for Lung Cancer Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 41 Global Market for Breast Cancer Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 42 Global Market for Leukemia Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 43 Global Market for Myeloma Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 44 Global Market for Colorectal Cancer Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 45 Global Market for Lymphoma Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 46 Global Market for Melanoma Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 47 Global Market for Kidney Cancer Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 48 Global Market for Bladder Cancer Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 49 Global Market for Head and Neck Cancer Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 50 Global Market for Stomach Cancer Treatment, by Category, Through 2021 ($ Millions)
  • TABLE 51 Global Market for Treatment of Other Types of Cancer, by Category, Through 2021 ($ Millions)
  • TABLE 52 Global Market for Oncolytic Virotherapy, Through 2021 ($ Millions)
  • TABLE 53 Global Market for Oncolytic Virotherapy, by Region, Through 2021 ($ Millions)
  • TABLE 54 Global Market for Oncolytic Virotherapy, by Indication, Through 2021 ($ Millions)

List of Figures

  • FIGURE 1 Summary Figure: Global Market for Cancer Immunotherapy, by Region, 2015-2021 ($ Millions)
  • FIGURE 2 Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 3 Annual Incidence and Mortality Data for Lung Cancer in Five E.U. Countries, 1975-2012 (Number of Cases)
  • FIGURE 4 Annual Incidence and Mortality Data for Lung Cancer in Japan, 1975-2015 (Number of Cases)
  • FIGURE 5 Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2012 (Number of Cases)
  • FIGURE 6 Five-Year Survival Rates, by Lung Cancer Stage (%)
  • FIGURE 7 Five-Year Survival Rates for Lung Cancer in the U.S., 1975-2008 (%)
  • FIGURE 8 Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 9 Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2012 (Number of Cases)
  • FIGURE 10 Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2012 (Number of Cases)
  • FIGURE 11 Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2012 (Number of Cases)
  • FIGURE 12 Five-Year Survival Rates, by Breast Cancer Stage (%)
  • FIGURE 13 Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 14 Annual Incidence and Mortality Data for Colorectal Cancer in Five E.U. Countries, 1975-2012 (Number of Cases)
  • FIGURE 15 Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2015 (Number of Cases)
  • FIGURE 16 Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975- 2012 (Number of Cases)
  • FIGURE 17 Five-Year Survival Rates, by Colorectal Cancer Stage (%)
  • FIGURE 18 Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2012 (Number of Cases)
  • FIGURE 19 Annual Incidence and Mortality Data for Stomach Cancer in Five E.U. Countries, 1975-2012 (Number of Cases)
  • FIGURE 20 Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2015 (Number of Cases)
  • FIGURE 21 Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975- 2012 (Number of Cases)
  • FIGURE 22 Five-Year Survival Rates, by Stomach Cancer Stage (%)
  • FIGURE 23 Annual Incidence and Mortality Data for Head and Neck Cancer in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 24 Annual Incidence and Mortality Data for Head and Neck Cancer in Five E.U. Countries, 1975- 2012 (Number of Cases)
  • FIGURE 25 Annual Incidence and Mortality Data for Head and Neck Cancer in Japan, 1975-2015 (Number of Cases)
  • FIGURE 26 Annual Incidence and Mortality Data for Head and Neck Cancer in the Rest of the World, 1975-2012 (Number of Cases)
  • FIGURE 27 Five-Year Survival Rates, by Head and Neck Cancer Stage (%)
  • FIGURE 28 Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 29 Annual Incidence and Mortality Data for Leukemia in Five E.U. Countries, 1975-2012 (Number of Cases)
  • FIGURE 30 Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2015 (Number of Cases)
  • FIGURE 31 Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2012 (Number of Cases)
  • FIGURE 32 Annual Incidence and Mortality Data for Cervical Cancer in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 33 Annual Incidence and Mortality Data for Cervical Cancer in Five E.U. Countries, 1975-2012 (Number of Cases)
  • FIGURE 34 Annual Incidence and Mortality Data for Cervical Cancer in Japan, 1975-2015 (Number of Cases)
  • FIGURE 35 Annual Incidence and Mortality Data for Cervical Cancer in the Rest of the World, 1975-2012 (Number of Cases)
  • FIGURE 36 Five-Year Survival Rates, by Cervical Cancer Stage (%)
  • FIGURE 37 Annual Incidence and Mortality Data for Prostate Cancer in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 38 Annual Incidence and Mortality Data for Prostate Cancer in Five E.U. Countries, 1975-2012 (Number of Cases)
  • FIGURE 39 Annual Incidence and Mortality Data for Prostate Cancer in Japan, 1975-2015 (Number of Cases)
  • FIGURE 40 Annual Incidence and Mortality Data for Prostate Cancer in the Rest of the World, 1975- 2012 (Number of Cases)
  • FIGURE 41 Five-Year Survival Rates, by Prostate Cancer Stage (%)
  • FIGURE 42 Annual Incidence and Mortality Data for Melanoma in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 43 Annual Incidence and Mortality Data for Melanoma in Five E.U. Countries, 1975-2012 (Number of Cases)
  • FIGURE 44 Annual Incidence and Mortality Data for Melanoma in Japan, 1975-2015 (Number of Cases)
  • FIGURE 45 Annual Incidence and Mortality Data for Melanoma in the Rest of the World, 1975-2012 (Number of Cases)
  • FIGURE 46 Five-Year Survival Rates, by Melanoma Stage (%)
  • FIGURE 47 Annual Incidence and Mortality Data for Ovarian Cancer in the U.S., 1975-2015 (Number of Cases)
  • FIGURE 48 Annual Incidence and Mortality Data for Ovarian Cancer in Five E.U. Countries, 1975-2012 (Number of Cases)
  • FIGURE 49 Annual Incidence and Mortality Data for Ovarian Cancer in Japan, 1975-2015 (Number of Cases)
  • FIGURE 50 Annual Incidence and Mortality Data for Ovarian Cancer in the Rest of the World, 1975-2012 (Number of Cases)
  • FIGURE 51 Five-Year Survival Rates, by Ovarian Cancer Stage (%)
  • FIGURE 52 Market Share of Leaders in Cancer Immunotherapy, 2016 (%)
  • FIGURE 53 Global Market Share of Leaders in Oncolytic Virotherapy, 2021 (%)
Back to Top